Abstract 322P
Background
The COVID-19 pandemic has affected more than ten million people worldwide with nearly four lakh deaths. Cancer patients requiring continuum of care are facing difficulty accessing healthcare. Due to the risk of infection with COVID-19, their treatments have been rescheduled, elective procedures postponed, intravenous chemotherapies transitioned to oral medications, where possible, maintenance therapies deferred, and supportive care administered at home. Hence, we conducted a survey from the hospital patient registry to provide critical, up-to-date information about the impact of COVID-19 on cancer patients.
Methods
Patients taking treatment in the Department of Medical Oncology and Haematology at the American Oncology Institute, Hyderabad were given an online questionnaire upon consent. Details included age, cancer type, disease stage, treatment phase, delay in hospital appointment, procuring essential drugs including pain medicine, investigations, average time delay, impact on mental health, interpersonal relationships, deferring treatment due to fear of infection amongst other questions. Survey is also available in the local language besides English.
Results
A total of 200 patients participated in the survey with majority in the age group of 26-75 years (95.5%), 60% being female and the commonest cancers being breast (22%) and lung (16.5%) respectively. Patients receiving chemotherapy and immunotherapy were 58% and 3.9% with most being stage 3 (29%) and 4 (48.5%). Treatment delays were faced by 32% for various reasons while mental health impact in 67% patients. Majority of the patients expressed being at higher risk from COVID-19, with 35.8% agreeing upon continuation of chemotherapy and 66% preferring transition from injectable to oral medication. Forty five percent were aware of COVID-19 prophylaxis, while 85% discussed continuation or deferring treatment with their respective care giver.
Conclusions
This survey was a cooperative effort across many physicians, nurses and patients to provide critical, up-to-date information about the impact of the COVID-19 pandemic on cancer patients. Completing this short 10-minute survey or questionnaire will help health care to identify COVID-19 related issues in the community.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session